Centella
ApprovedSmall molecule
Centella is one of 46 small molecule programs targeting Hemorrhoid. It is currently in Approved.
2
Indications
2
Total Trials
0
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
72 competitors in Hemorrhoid
#DrugCompanyPhaseTrials
1Isordil
AstraZenecaApproved
Nitrostat
VViatris Specialty LLC
Approved
Marcaine
IInnocoll
Approved
Ketalar
AAultman Health Foundation
Approved
Cardizem
BBausch Health Americas, Inc.
Approved
Xylocaine
MMEDRx USA, Inc.
Approved
Celestone
SSchering-Plough
Approved
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Neo-Synephrine
EExela Pharma Sciences, LLC.
Approved
EXPAREL
Pacira Pharmaceuticals, IncApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Centella. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- UUniversity of Roma La Sapienza